Biogen reports positive drug data

Biogen Idec Inc. of Cambridge today reported "positive results" for a Phase II study of a potential treatment for heart failure patients.

The results were published in the Journal of the American College of Cardiology, the company said.

Patients with heart failure are at risk of developing worsening kidney function, and the company's Adentri drug candidate, used in conjunction with standard heart failure therapy, shows promise in preserving renal function for patients with heart failure, Biogen Idec said.

According to the American Heart Association, 5 million people suffer from heart failure in the United States, the company said.
(By Chris Reidy, Globe staff)